Skip to main content

Are you a legal professional? Visit our professional site

Please enter a legal issue and/or a location
Begin typing to search, use arrow keys to navigate, use enter to select

Study: Anemia Drugs May Pose Death Risk

By Admin on February 27, 2008 8:25 AM

Anemia drugs like Aranesp and Procrit can increase the risk of death and blood clots, according to a study published in the Journal of the American Medical Association (JAMA). These drugs, called erythropoiesis-stimulating agents (ESAs), are used in treatment of chemotherapy-associated anemia in certain cancer patients. The study, which looked at 89 clinical trials, found a 10 percent increase in risk of death and a 57 percent increase in risk of blood clotting (called venous thromboembolism) in patients being treated with ESAs. Aranesp is manufactured by Amgen, while Procrit is a product of Johnson & Johnson. On March 13, the U.S. Food and Drug Administration (FDA) will hold an advisory committee hearing on the safety of ESAs. In early January 2008, FDA issued an update on safety information related to ESAs.

You Don’t Have To Solve This on Your Own – Get a Lawyer’s Help

Meeting with a lawyer can help you understand your options and how to best protect your rights. Visit our attorney directory to find a lawyer near you who can help.

Or contact an attorney near you:
Copied to clipboard

Find a Lawyer

More Options